Comparative Pharmacology
Head-to-head clinical analysis: DIENESTROL versus ESTRONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIENESTROL versus ESTRONE.
DIENESTROL vs ESTRONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic nonsteroidal estrogen that binds to estrogen receptors, activating transcription of estrogen-responsive genes, leading to effects similar to endogenous estrogens.
Estrone is a natural estrogen that binds to estrogen receptors (ERα and ERβ) in target tissues, modulating gene expression and exerting estrogenic effects on reproductive, skeletal, and cardiovascular systems.
0.1 to 0.5 mg orally once daily for estrogen replacement therapy; 0.5 to 1.0 mg orally once daily for prostatic carcinoma.
For menopausal hormone therapy: 0.625-5 mg orally once daily; or 0.1-0.5 mg transdermally once weekly; or 2.5-5 mg intramuscularly every 2-4 weeks.
None Documented
None Documented
Clinical Note
moderateEstrone + Gatifloxacin
"The risk or severity of adverse effects can be increased when Estrone is combined with Gatifloxacin."
Clinical Note
moderateEstrone sulfate + Gatifloxacin
"The risk or severity of adverse effects can be increased when Estrone sulfate is combined with Gatifloxacin."
Clinical Note
moderateEstrone + Rosoxacin
"The risk or severity of adverse effects can be increased when Estrone is combined with Rosoxacin."
Clinical Note
moderateEstrone sulfate + Rosoxacin
Terminal elimination half-life is approximately 24-48 hours, longer with hepatic impairment.
Terminal elimination half-life is 24-36 hours; due to enterohepatic recirculation and slow clearance of conjugates, clinical effects persist for several days after discontinuation.
Primarily renal (40-60% as glucuronide conjugates) and biliary/fecal (30-50% with enterohepatic recycling).
Renal (approximately 60-80% as glucuronide and sulfate conjugates), biliary/fecal (20-40%)
Category C
Category C
Estrogen
Estrogen
"The risk or severity of adverse effects can be increased when Estrone sulfate is combined with Rosoxacin."